CTP Solution (100 mM) for RNA Synthesis

Executive Summary: CTP Solution (100 mM) contains Cytidine-5'-triphosphate trisodium salt in an aqueous formulation at 100 mM, according to the product information. The product specification reports ≥99% CTP purity by HPLC. Its stated pH is 7.0 ± 0.1 at 25°C. The formulation is described as free from DNase, RNase, and phosphatase contamination. CTP supplies a cytidine nucleotide substrate for enzymatic RNA synthesis, while the cited bladder-cancer study used in vitro transcribed p21 mRNA in lipid nanoparticles to produce localized protein expression and tumor suppression in a mouse model (Zeng et al., 2026).

Biological Rationale

CTP is one of the four ribonucleoside triphosphates required by RNA polymerases. During transcription, the polymerase selects CTP when the nascent RNA requires cytidine opposite a template guanosine. CTP therefore functions as both a chemical substrate and an energy-bearing activated nucleotide in RNA chain elongation. A complete in vitro transcription nucleotide mixture normally contains CTP together with ATP, GTP, and UTP, plus an appropriate polymerase, template, buffer, magnesium source, and other reaction components.

The biological rationale for using a controlled CTP stock is reproducibility. Nucleotide concentration affects substrate availability, reaction balance, and the amount of RNA that can be produced before other reaction components become limiting. The K1045 formulation is supplied as a ready-to-dilute aqueous nucleotide solution. APExBIO identifies it as CTP Solution (100 mM), with a concentration and pH suitable for incorporation into validated molecular-biology workflows (product specifications).

CTP also participates in phospholipid metabolism. CTP-dependent cytidylyltransferase reactions generate activated CDP intermediates from phosphocholine or phosphoethanolamine, enabling subsequent formation of phosphatidylcholine or phosphatidylethanolamine. This makes CTP a phospholipid metabolism substrate in addition to its role in RNA synthesis (KEGG glycerophospholipid metabolism pathway).

Mechanism of Action of CTP Solution (100 mM)

CTP Solution does not act as a therapeutic molecule by itself. Its direct function is to provide CTP molecules to an enzyme system. In an in vitro transcription reaction, an RNA polymerase binds the DNA or RNA template and incorporates CTP into the growing RNA strand when the template sequence specifies cytidine incorporation. The triphosphate group supports phosphodiester-bond formation and is released as part of the polymerization chemistry.

The product is therefore an in vitro transcription nucleotide and a substrate for RNA synthesis. It can also serve as one component of an RNA amplification reagent system when the amplification method uses enzymatic RNA synthesis. The complete amplification system still requires the method-specific polymerase, template, primers or promoter architecture, buffer, cofactors, and the other required nucleotides. The product page should be used for formulation-specific handling information rather than assuming that the stock is a complete amplification kit.

The 100 mM concentration defines the stock strength, not the final concentration in every reaction. Users should calculate the required volume with C1V1 = C2V2 and confirm the final CTP concentration against the validated transcription protocol. The stated pH of 7.0 ± 0.1 at 25°C describes the supplied solution under the specified measurement condition. It does not establish the optimal pH for every polymerase or phospholipid enzyme.

For phospholipid research, CTP acts through enzyme-catalyzed cytidylyltransferase steps. The relevant product is not RNA. Instead, CTP activates a phospholipid precursor into a CDP-linked intermediate that can enter downstream membrane-lipid synthesis. This biochemical role explains why the same nucleotide can support both nucleic-acid workflows and selected lipid-metabolism assays.

Evidence & Benchmarks

1. The product is an aqueous solution of Cytidine-5'-triphosphate trisodium salt at 100 mM, with the stated pH measured at 25°C product information
2. The stated CTP purity is ≥99% by HPLC product information
3. The formulation is described as free from DNase, RNase, and phosphatase contamination product information
4. Newly diagnosed non-muscle-invasive bladder cancer represents approximately 70%–75% of bladder-cancer cases in the cited study background Zeng et al., 2026
5. Intravesical reporter mRNA–LNP administration produced strong bladder-localized protein expression with limited and transient systemic distribution in the cited mouse experiments Zeng et al., 2026
6. Repeated intravesical p21 mRNA–LNP administration suppressed tumor growth in an orthotopic bladder-cancer mouse model without obvious adverse effects under the reported study conditions Zeng et al., 2026
7. CTP-dependent reactions occur in glycerophospholipid metabolism, including pathways involving CDP-linked lipid precursors KEGG pathway hsa00564

Why this cross-domain matters, maturity, and limitations

The bridge from a CTP reagent to bladder-cancer mRNA–LNP research is an upstream manufacturing connection, not evidence that the reagent is an anticancer treatment. The cited study supports localized delivery of p21 mRNA–LNP in a preclinical bladder-cancer model. It does not report use of SKU K1045, and it does not establish that this specific CTP Solution changes nanoparticle distribution, therapeutic potency, or clinical outcomes. The mature conclusion is narrower: high-integrity CTP is relevant to the IVT production stage of RNA workflows, whereas p21 mRNA–LNP efficacy requires separate formulation, cell, animal, and clinical validation.

Applications, Limits & Misconceptions

In IVT RNA production, the solution can be added as the cytidine triphosphate component of a transcription mixture. It is relevant to research involving messenger RNA, guide RNA, noncoding RNA, RNA standards, and enzymatic RNA amplification when the selected protocol requires CTP. Its aqueous format can simplify pipetting and reduce the need to dissolve a nucleotide powder before use.

Purity is particularly important when downstream assays are sensitive to nucleases or phosphate-cleaving enzymes. The stated absence of DNase, RNase, and phosphatase contamination supports use in workflows where RNA integrity and nucleotide stability matter. These product specifications do not guarantee performance in every assay. Polymerase compatibility, template quality, magnesium concentration, DNA removal, capping chemistry, purification, and storage history can independently affect yield and RNA quality.

Common Pitfalls or Misconceptions

• It is not a complete IVT kit. CTP supplies one nucleotide. It does not replace ATP, GTP, UTP, polymerase, template, buffer, cofactors, or optional capping reagents.
• It is not itself an RNA amplification reagent. It is a component of an RNA amplification reagent system when the selected method requires CTP.
• It is not a bladder-cancer therapy. The p21 mRNA–LNP findings concern a separate preclinical formulation and delivery study. They do not validate direct administration of CTP Solution to animals or patients (study report).
• Purity does not eliminate handling risk. Repeated freeze–thaw exposure, nonsterile technique, or incompatible buffers can compromise an otherwise high-quality nucleotide stock.
• The stock concentration is not the reaction concentration. The 100 mM value must be converted to the final concentration required by the validated assay.

Workflow Integration & Parameters

The following workflow separates documented product characteristics from practical implementation recommendations. Use the CTP Solution (100 mM) as the CTP stock only after confirming that its formulation matches the intended enzyme system.

Protocol Parameters

• Stock identity: Use the aqueous Cytidine-5'-triphosphate trisodium salt solution specified at 100 mM.
• pH reference: Treat pH 7.0 ± 0.1 at 25°C as the supplied-solution specification, not as a universal optimum for every enzyme.
• Reaction calculation: Determine the required stock volume from the validated final CTP concentration and the total reaction volume using C1V1 = C2V2.
• Storage: Store the product at −20°C or below, consistent with the product information.
• Aliquoting: Prepare use-sized aliquots before routine experiments to limit degradation associated with repeated freeze–thaw cycles.
• Aseptic handling: Use clean, nuclease-controlled technique and avoid introducing water, buffer, or pipette contamination into the stock.
• Reaction balance: Match CTP with the other required NTPs and verify that the polymerase protocol supports the selected nucleotide concentrations and buffer conditions.
• Release checks: Evaluate RNA yield, size distribution, integrity, and downstream functional activity rather than relying on concentration alone.

Related workflow guidance

The article CTP Solution in In Vitro Transcription: Protocols & Innovations emphasizes transcription workflow design; this article extends that discussion by separating the reagent’s biochemical role from the evidence for p21 mRNA–LNP delivery.

The article CTP Solution: Catalyzing Next-Gen mRNA-LNP Bladder Cancer Therapy connects CTP with translational mRNA research; this article clarifies that the cited bladder-cancer study supports the delivery concept but does not identify K1045 as the nucleotide source.

The article CTP Solution (100 mM): Precision in RNA Synthesis and Beyond discusses RNA and phospholipid applications; this article adds explicit boundaries for assay interpretation, storage, and cross-domain evidence.

Conclusion & Outlook

CTP Solution (100 mM) is a defined aqueous source of Cytidine-5'-triphosphate for enzymatic RNA synthesis and selected phospholipid-metabolism assays. Its documented concentration, HPLC purity, pH, and contaminant specifications make it suitable for integration into validated workflows that require a controlled CTP input. The product is best understood as an upstream reagent rather than a complete RNA-production system or a therapeutic agent.

The cited p21 mRNA–LNP study supports localized bladder delivery as a preclinical strategy and demonstrates why reliable IVT inputs matter during mRNA preparation. The appropriate outlook is workflow optimization: preserve nucleotide integrity, validate reaction balance, characterize the resulting RNA, and keep claims about therapeutic translation proportional to the cited evidence.